T1	tradename 0 8	ADCETRIS
T2	nanoparticle 10 30	brentuximab vedotin)
T3	tradename 137 145	ADCETRIS
T4	tradename 208 226	ADCETRIS. ADCETRIS
T5	nanoparticle 228 248	brentuximab vedotin)
T6	routeofadministration 268 279	intravenous
T7	fdaapprovaldate 307 311	2011
T8	adversereaction 321 370	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
T9	tradename 512 520	ADCETRIS
T10	tradename 803 811	ADCETRIS
T11	chemoclass 817 830	CD30-directed
T12	nanoparticle 831 854	antibody-drug conjugate
T13	indication 908 924	Hodgkin lymphoma
T14	indication 1114 1153	Systemic anaplastic large cell lymphoma
T15	routeofadministration 1663 1674	intravenous
T16	frequency 1700 1715	every 3 weeks.
T17	dose 1751 1760	1.8 mg/kg
T18	adversereaction 2307 2329	Peripheral neuropathy:
T19	adversereaction 2426 2461	Anaphylaxis and infusion reactions:
T20	adversereaction 2468 2485	infusion reaction
T21	adversereaction 2523 2534	anaphylaxis
T22	adversereaction 2597 2620	Hematologic toxicities:
T23	tradename 2673 2682	ADCETRIS.
T24	adversereaction 2724 2748	Grade 3 or 4 neutropenia
T25	adversereaction 2870 2918	Serious infections and opportunistic infections:
T26	adversereaction 2965 3002	bacterial, fungal or viral infections
T27	adversereaction 3020 3041	Tumor lysis syndrome:
T28	adversereaction 3138 3153	Hepatotoxicity:
T29	adversereaction 3206 3237	Serious dermatologic reactions:
T30	adversereaction 3333 3355	Embryo-fetal toxicity:
T31	adversereaction 3587 3740	neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough,
T32	adversereaction 3745 3753	vomiting
T33	company 3808 3830	Seattle Genetics, Inc.
T34	activeingredient 4110 4140	monomethyl auristatin E (MMAE)
T35	activeingredient 4292 4296	MMAE
T36	adversereaction 4552 4600	PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML)
T37	indication 4632 4648	Hodgkin Lymphoma
T38	indication 4655 4694	Systemic Anaplastic Large Cell Lymphoma
T39	adversereaction 4918 4939	Peripheral Neuropathy
T40	adversereaction 4946 4980	Anaphylaxis and Infusion Reactions
T41	adversereaction 4987 5009	Hematologic Toxicities
T42	adversereaction 5016 5063	Serious Infections and Opportunistic Infections
T43	adversereaction 5070 5090	Tumor Lysis Syndrome
T44	adversereaction 5097 5159	Increased Toxicity in the Presence of Severe Renal Impairment
T45	adversereaction 5166 5242	Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
T46	adversereaction 5249 5263	Hepatotoxicity
T47	adversereaction 5270 5312	Progressive Multifocal Leukoencephalopathy
T48	adversereaction 5320 5350	Serious Dermatologic Reactions
T49	adversereaction 5358 5379	Embryo-Fetal Toxicity
T50	tradename 5520 5528	ADCETRIS
T51	tradename 5544 5552	ADCETRIS
T52	indication 5976 5992	Hodgkin Lymphoma
T53	indication 6000 6039	Systemic Anaplastic Large Cell Lymphoma
T54	tradename 6506 6514	ADCETRIS
T55	indication 6610 6626	Hodgkin Lymphoma
T56	tradename 6627 6635	ADCETRIS
T57	nanoparticle 6637 6657	brentuximab vedotin)
T58	indication 6702 6723	Hodgkin lymphoma (HL)
T59	indication 7235 7274	Systemic Anaplastic Large Cell Lymphoma
T60	tradename 7275 7283	ADCETRIS
T61	indication 7328 7375	systemic anaplastic large cell lymphoma (sALCL)
T62	tradename 7851 7859	ADCETRIS
T63	routeofadministration 7866 7877	intravenous
T64	frequency 7903 7916	every 3 weeks
T65	tradename 8041 8049	ADCETRIS
T66	dose 8120 8142	1.8 mg/kg up to 180 mg
T67	dose 8269 8291	1.8 mg/kg up to 180 mg
T68	dose 8430 8452	1.2 mg/kg up to 120 mg
T69	dose 8805 8815	1.2 mg/kg.
T70	tradename 8852 8860	ADCETRIS
T71	tradename 8912 8920	ADCETRIS
T72	tradename 9271 9279	ADCETRIS
T73	dose 9283 9293	1.2 mg/kg.
T74	tradename 9384 9392	ADCETRIS
T75	routeofadministration 9399 9410	intravenous
T76	tradename 9447 9455	ADCETRIS
T77	indication 9604 9614	anticancer
T78	tradename 9940 9948	ADCETRIS
T79	nanoparticle 10049 10069	brentuximab vedotin.
T80	tradename 10771 10779	ADCETRIS
T81	nanoparticle 11121 11141	brentuximab vedotin.
T82	tradename 11239 11247	ADCETRIS
T83	dose 11460 11465	50 mg
T84	nanoparticle 11469 11488	brentuximab vedotin
T85	tradename 11630 11638	ADCETRIS
T86	adversereaction 11829 11850	Peripheral Neuropathy
T87	tradename 11851 11859	ADCETRIS
T88	adversereaction 11879 11900	peripheral neuropathy
T89	adversereaction 11942 11969	peripheral motor neuropathy
T90	tradename 11996 12012	ADCETRIS-induced
T91	adversereaction 12013 12034	peripheral neuropathy
T92	indication 12057 12059	HL
T93	indication 12064 12069	sALCL
T94	adversereaction 12128 12139	neuropathy.
T95	adversereaction 12275 12286	neuropathy,
T96	adversereaction 12304 12314	neuropathy
T97	adversereaction 12387 12398	neuropathy,
T98	adversereaction 12407 12499	hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain,
T99	adversereaction 12503 12512	weakness.
T100	adversereaction 12553 12574	peripheral neuropathy
T101	tradename 12634 12642	ADCETRIS
T102	adversereaction 12679 12741	Anaphylaxis and Infusion Reactions Infusion-related reactions,
T103	adversereaction 12752 12764	anaphylaxis,
T104	tradename 12784 12793	ADCETRIS.
T105	adversereaction 12833 12844	anaphylaxis
T106	tradename 12911 12919	ADCETRIS
T107	adversereaction 12971 12996	infusion-related reaction
T108	co-administereddrug 13227 13241	acetaminophen,
T109	co-administereddrug 13245 13259	antihistamine,
T110	co-administereddrug 13266 13281	corticosteroid.
T111	adversereaction 13348 13370	Hematologic Toxicities
T112	adversereaction 13405 13416	neutropenia
T113	adversereaction 13421 13456	Grade 3 or Grade 4 thrombocytopenia
T114	adversereaction 13460 13466	anemia
T115	tradename 13482 13491	ADCETRIS.
T116	adversereaction 13493 13512	Febrile neutropenia
T117	tradename 13551 13560	ADCETRIS.
T118	tradename 13626 13634	ADCETRIS
T119	adversereaction 13703 13728	Grade 3 or 4 neutropenia.
T120	adversereaction 13761 13785	Grade 3 or 4 neutropenia
T121	tradename 13884 13892	ADCETRIS
T122	adversereaction 13935 14030	Serious Infections and Opportunistic Infections Serious infections and opportunistic infections
T123	adversereaction 14039 14061	pneumonia, bacteremia,
T124	adversereaction 14066 14088	sepsis or septic shock
T125	tradename 14160 14169	ADCETRIS.
T126	adversereaction 14255 14294	bacterial, fungal, or viral infections.
T127	adversereaction 14300 14320	Tumor Lysis Syndrome
T128	adversereaction 14413 14434	tumor lysis syndrome.
T129	adversereaction 14487 14548	Increased Toxicity in the Presence of Severe Renal Impairment
T130	adversereaction 14605 14611	deaths
T131	activeingredient 14729 14733	MMAE
T132	tradename 14907 14915	ADCETRIS
T133	adversereaction 15047 15122	Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
T134	adversereaction 15179 15185	deaths
T135	tradename 15323 15331	ADCETRIS
T136	adversereaction 15463 15477	Hepatotoxicity
T137	adversereaction 15495 15510	hepatotoxicity,
T138	adversereaction 15521 15536	fatal outcomes,
T139	tradename 15573 15582	ADCETRIS.
T140	tradename 15734 15742	ADCETRIS
T141	tradename 15752 15760	ADCETRIS
T142	adversereaction 15980 15994	hepatotoxicity
T143	tradename 16054 16063	ADCETRIS.
T144	adversereaction 16139 16181	Progressive Multifocal Leukoencephalopathy
T145	adversereaction 16214 16217	PML
T146	adversereaction 16222 16227	death
T147	tradename 16249 16265	ADCETRIS-treated
T148	tradename 16291 16299	ADCETRIS
T149	adversereaction 16453 16456	PML
T150	tradename 16563 16571	ADCETRIS
T151	adversereaction 16605 16608	PML
T152	tradename 16625 16633	ADCETRIS
T153	adversereaction 16659 16662	PML
T154	adversereaction 16683 16744	Serious Dermatologic Reactions Stevens-Johnson syndrome (SJS)
T155	adversereaction 16749 16782	toxic epidermal necrolysis (TEN),
T156	adversereaction 16793 16808	fatal outcomes,
T157	tradename 16833 16842	ADCETRIS.
T158	adversereaction 16847 16850	SJS
T159	adversereaction 16854 16857	TEN
T160	tradename 16878 16886	ADCETRIS
T161	adversereaction 16937 16958	Embryo-Fetal Toxicity
T162	tradename 17012 17020	ADCETRIS
T163	tradename 17108 17116	ADCETRIS
T164	nanoparticle 17178 17197	Brentuximab vedotin
T165	adversereaction 17205 17229	embryo-fetal toxicities,
T166	adversereaction 17254 17280	decreased embryo viability
T167	adversereaction 17285 17305	fetal malformations,
T168	adversereaction 17796 17817	Peripheral neuropathy
T169	adversereaction 17865 17899	Anaphylaxis and Infusion Reactions
T170	adversereaction 17947 17969	Hematologic Toxicities
T171	adversereaction 18017 18064	Serious Infections and Opportunistic Infections
T172	adversereaction 18112 18132	Tumor Lysis Syndrome
T173	adversereaction 18180 18241	Increased Toxicity in the Presence of Severe Renal Impairment
T174	adversereaction 18291 18366	Increased Toxicity in the Presence of Moderate or Severe Hepatic Impairment
T175	adversereaction 18415 18429	Hepatotoxicity
T176	adversereaction 18477 18519	Progressive Multifocal Leukoencephalopathy
T177	adversereaction 18566 18596	Serious Dermatologic Reactions
T178	adversereaction 18687 18708	Embryo-Fetal Toxicity
T179	tradename 19040 19048	ADCETRIS
T180	adversereaction 19215 19368	neutropenia, peripheral sensory neuropathy, fatigue, nausea, anemia, upper respiratory tract infection, diarrhea, pyrexia, rash, thrombocytopenia, cough,
T181	adversereaction 19373 19382	vomiting.
T182	indication 19587 19603	Hodgkin Lymphoma
T183	tradename 19604 19612	ADCETRIS
T184	indication 19646 19648	HL
T185	dose 19736 19745	1.8 mg/kg
T186	routeofadministration 19746 19759	intravenously
T187	frequency 19760 19774	every 3 weeks.
T188	duration 19809 19817	27 weeks
T189	duration 19826 19840	3 to 56 weeks)
T190	adversereaction 19952 20121	neutropenia, peripheral sensory neuropathy, fatigue, upper respiratory tract infection, nausea, diarrhea, anemia, pyrexia, thrombocytopenia, rash, abdominal pain, cough,
T191	adversereaction 20126 20155	vomiting. Pulmonary Toxicity
T192	indication 20200 20202	HL
T193	tradename 20216 20224	ADCETRIS
T194	adversereaction 20301 20319	pulmonary toxicity
T195	adversereaction 20460 20465	cough
T196	adversereaction 20470 20478	dyspnea.
T197	tradename 20671 20679	ADCETRIS
T198	indication 20758 20797	Systemic Anaplastic Large Cell Lymphoma
T199	tradename 20798 20806	ADCETRIS
T200	indication 20839 20844	sALCL
T201	dose 20932 20941	1.8 mg/kg
T202	routeofadministration 20942 20955	intravenously
T203	frequency 20956 20970	every 3 weeks.
T204	duration 21005 21013	24 weeks
T205	duration 21022 21036	3 to 56 weeks)
T206	adversereaction 21148 21225	neutropenia, anemia, peripheral sensory neuropathy, fatigue, nausea, pyrexia,
T207	adversereaction 21232 21241	diarrhea,
T208	adversereaction 21246 21251	pain.
T209	adversereaction 21646 21703	Neutropenia* Anemia* Thrombocytopenia* Lymphadenopathy
T210	adversereaction 21731 21820	Peripheral sensory neuropathy Peripheral motor neuropathy Headache Dizziness
T211	adversereaction 21876 21924	Fatigue Pyrexia Chills Pain Edema peripheral
T212	adversereaction 21954 21987	Upper respiratory tract infection
T213	adversereaction 22016 22068	Nausea Diarrhea Abdominal pain Vomiting Constipation
T214	adversereaction 22109 22153	Rash Pruritus Alopecia Night sweats Dry skin
T215	indication 22579 22581	HL
T216	indication 22611 22616	sALCL
T217	adversereaction 22787 22794	Dyspnea
T218	adversereaction 22811 22829	Oropharyngeal pain
T219	adversereaction 22892 22902	Arthralgia
T220	adversereaction 22915 22922	Myalgia
T221	adversereaction 22936 22945	Back pain
T222	adversereaction 22959 22976	Pain in extremity
T223	adversereaction 22994 23007	Muscle spasms
T224	adversereaction 23043 23051	Insomnia
T225	adversereaction 23065 23072	Anxiety
T226	adversereaction 23125 23143	Decreased appetite
T227	adversereaction 23174 23190	Weight decreased
T228	adversereaction 23262 23280	Infusion reactions
T229	adversereaction 23295 23306	anaphylaxis
T230	adversereaction 23368 23394	infusion-related reactions
T231	adversereaction 23449 23475	infusion-related reactions
T232	adversereaction 23577 23603	infusion-related reactions
T233	adversereaction 23609 23615	chills
T234	adversereaction 23622 23628	nausea
T235	adversereaction 23635 23642	dyspnea
T236	adversereaction 23649 23657	pruritus
T237	adversereaction 23664 23671	pyrexia
T238	adversereaction 23682 23687	cough
T239	tradename 23840 23849	ADCETRIS.
T240	indication 23921 23923	HL
T241	adversereaction 23932 23959	peripheral motor neuropathy
T242	adversereaction 23966 23980	abdominal pain
T243	adversereaction 23987 24005	pulmonary embolism
T244	adversereaction 24012 24023	pneumonitis
T245	adversereaction 24030 24042	pneumothorax
T246	adversereaction 24049 24063	pyelonephritis
T247	adversereaction 24074 24081	pyrexia
T248	indication 24160 24165	sALCL
T249	adversereaction 24171 24183	septic shock
T250	adversereaction 24190 24217	supraventricular arrhythmia
T251	adversereaction 24224 24241	pain in extremity
T252	adversereaction 24252 24275	urinary tract infection
T253	adversereaction 24383 24413	PML, Stevens-Johnson syndrome,
T254	adversereaction 24418 24439	tumor lysis syndrome.
T255	adversereaction 24536 24547	neutropenia
T256	adversereaction 24558 24587	peripheral sensory neuropathy
T257	indication 24807 24809	HL
T258	indication 24813 24818	sALCL
T259	adversereaction 24824 24853	peripheral sensory neuropathy
T260	adversereaction 24863 24890	peripheral motor neuropathy
T261	tradename 25009 25018	ADCETRIS.
T262	adversereaction 25261 25280	febrile neutropenia
T263	adversereaction 25345 25359	hepatotoxicity
T264	adversereaction 25410 25413	PML
T265	adversereaction 25474 25514	 infections and opportunistic infections
T266	adversereaction 25590 25604	hyperglycemia.
T267	adversereaction 25634 25646	Pancreatitis
T268	adversereaction 25808 25835	Toxic epidermal necrolysis,
T269	indication 25934 25936	HL
T270	indication 25941 25946	sALCL
T271	nanoparticle 26027 26046	brentuximab vedotin
T272	frequency 26047 26060	every 3 weeks
T273	nanoparticle 26424 26443	brentuximab vedotin
T274	adversereaction 26716 26742	infusion related reactions
T275	tradename 27540 27548	ADCETRIS
T276	activeingredient 27668 27698	monomethyl auristatin E (MMAE)
T277	activeingredient 27772 27776	MMAE
T278	tradename 27876 27884	ADCETRIS
T279	activeingredient 27913 27917	MMAE
T280	tradename 28009 28017	ADCETRIS
T281	activeingredient 28086 28090	MMAE
T282	tradename 28185 28193	ADCETRIS
T283	tradename 28266 28274	ADCETRIS
T284	activeingredient 28335 28339	MMAE
T285	tradename 28401 28409	ADCETRIS
T286	activeingredient 28456 28461	MMAE.
T287	tradename 28524 28532	ADCETRIS
T288	tradename 28599 28607	ADCETRIS
T289	tradename 28644 28652	ADCETRIS
T290	activeingredient 28712 28716	MMAE
T291	tradename 28824 28832	ADCETRIS
T292	tradename 29096 29104	ADCETRIS
T293	tradename 29192 29200	ADCETRIS
T294	nanoparticle 29262 29281	Brentuximab vedotin
T295	adversereaction 29289 29312	embryo-fetal toxicities
T296	indication 29472 29474	HL
T297	indication 29479 29485	sALCL.
T298	routeofadministration 29736 29747	intravenous
T299	dose 29757 29779	0.3, 1, 3, or 10 mg/kg
T300	nanoparticle 29780 29799	brentuximab vedotin
T301	adversereaction 29888 29911	embryo-fetal toxicities
T302	dose 29953 29967	3 and 10 mg/kg
T303	nanoparticle 30224 30243	brentuximab vedotin
T304	dose 30252 30259	3 mg/kg
T305	indication 30312 30314	HL
T306	indication 30318 30323	sALCL
T307	dose 30361 30370	1.8 mg/kg
T308	frequency 30371 30389	every three weeks.
T309	nanoparticle 30435 30454	brentuximab vedotin
T310	tradename 30612 30620	ADCETRIS
T311	tradename 30819 30827	ADCETRIS
T312	tradename 30902 30910	ADCETRIS
T313	tradename 31085 31093	ADCETRIS
T314	tradename 31314 31322	ADCETRIS
T315	activeingredient 31462 31493	monomethyl auristatin E (MMAE).
T316	nanoparticle 31530 31549	brentuximab vedotin
T317	activeingredient 31554 31558	MMAE
T318	dose 31602 31611	1.2 mg/kg
T319	tradename 31615 31623	ADCETRIS
T320	activeingredient 31954 31958	MMAE
T321	tradename 31973 31982	ADCETRIS)
T322	activeingredient 32120 32124	MMAE
T323	tradename 32361 32369	ADCETRIS
T324	activeingredient 32502 32507	MMAE.
T325	nanoparticle 32544 32563	brentuximab vedotin
T326	activeingredient 32568 32572	MMAE
T327	tradename 32629 32637	ADCETRIS
T328	activeingredient 32968 32972	MMAE
T329	tradename 33156 33165	ADCETRIS.
T330	tradename 33344 33352	ADCETRIS
T331	nanoparticle 33354 33374	brentuximab vedotin)
T332	chemoclass 33380 33393	CD30-directed
T333	nanoparticle 33394 33423	antibody-drug conjugate (ADC)
T334	chemoclass 33525 33553	microtubule disrupting agent
T335	activeingredient 33554 33559	MMAE,
T336	activeingredient 33620 33624	MMAE
T337	nanoparticle 33636 33655	Brentuximab vedotin
T338	molecularweight 33695 33703	153 kDa.
T339	activeingredient 33734 33738	MMAE
T340	nanoparticle 33780 33799	Brentuximab vedotin
T341	tradename 34024 34032	ADCETRIS
T342	nanoparticle 34034 34054	brentuximab vedotin)
T343	inactiveingredient 34228 34233	Water
T344	nanoparticle 34284 34303	brentuximab vedotin
T345	inactiveingredient 34361 34381	trehalose dihydrate,
T346	inactiveingredient 34392 34417	sodium citrate dihydrate,
T347	inactiveingredient 34429 34453	citric acid monohydrate,
T348	inactiveingredient 34469 34483	polysorbate 80
T349	inactiveingredient 34488 34493	water
T350	nanoparticle 34637 34656	Brentuximab vedotin
T351	nanoparticle 34663 34667	ADC.
T352	activeingredient 34745 34750	MMAE,
T353	chemoclass 34756 34785	microtubule disrupting agent.
T354	activeingredient 34787 34791	MMAE
T355	indication 34879 34889	anticancer
T356	tradename 34902 34910	ADCETRIS
T357	nanoparticle 34940 34943	ADC
T358	nanoparticle 35005 35011	ADC-CD
T359	activeingredient 35042 35046	MMAE
T360	activeingredient 35085 35089	MMAE
T361	nanoparticle 35293 35312	brentuximab vedotin
T362	dose 35314 35324	1.8 mg/kg)
T363	nanoparticle 35485 35504	brentuximab vedotin
T364	nanoparticle 35765 35784	brentuximab vedotin
T365	nanoparticle 35951 35955	ADC,
T366	activeingredient 35956 35961	MMAE,
T367	nanoparticle 36060 36064	ADC.
T368	nanoparticle 36094 36097	ADC
T369	activeingredient 36102 36106	MMAE
T370	nanoparticle 36167 36170	ADC
T371	nanoparticle 36256 36259	ADC
T372	plasmahalflife 36337 36349	4 to 6 days.
T373	dose 36403 36420	1.2 to 2.7 mg/kg.
T374	nanoparticle 36441 36444	ADC
T375	tmax 36458 36472	within 21 days
T376	frequency 36478 36490	every 3-week
T377	tradename 36501 36510	ADCETRIS,
T378	nanoparticle 36591 36594	ADC
T379	frequency 36635 36647	every 3-week
T380	activeingredient 36697 36701	MMAE
T381	tmax 36728 36740	1 to 3 days.
T382	nanoparticle 36757 36761	ADC,
T383	activeingredient 36778 36782	MMAE
T384	tmax 36796 36810	within 21 days
T385	tmax 36816 36828	every 3 week
T386	tradename 36839 36848	ADCETRIS.
T387	activeingredient 36850 36854	MMAE
T388	tradename 36908 36916	ADCETRIS
T389	activeingredient 37056 37060	MMAE
T390	activeingredient 37114 37118	MMAE
T391	activeingredient 37206 37210	MMAE
T392	volumeofdistribution 37389 37402	6&#x2013;10 L
T393	nanoparticle 37407 37411	ADC.
T394	activeingredient 37497 37501	MMAE
T395	activeingredient 37516 37535	brentuximab vedotin
T396	activeingredient 37585 37589	MMAE
T397	activeingredient 37714 37718	MMAE
T398	activeingredient 37766 37770	MMAE
T399	activeingredient 37866 37870	MMAE
T400	activeingredient 37935 37939	MMAE
T401	nanoparticle 37992 37996	ADC.
T402	dose 38067 38076	1.8 mg/kg
T403	tradename 38080 38089	ADCETRIS.
T404	activeingredient 38121 38125	MMAE
T405	nanoparticle 38154 38157	ADC
T406	tradename 38168 38176	ADCETRIS
T407	activeingredient 38263 38268	MMAE,
T408	activeingredient 38347 38351	MMAE
T409	nanoparticle 38676 38696	brentuximab vedotin.
T410	nanoparticle 38812 38831	brentuximab vedotin
T411	activeingredient 38855 38860	MMAE)
T412	activeingredient 38887 38891	MMAE
T413	activeingredient 39041 39045	MMAE
T414	chemoclass 39051 39080	microtubule disrupting agent.
T415	activeingredient 39082 39086	MMAE
T416	nanoparticle 39234 39253	brentuximab vedotin
T417	activeingredient 39257 39261	MMAE
T418	nanoparticle 39372 39391	brentuximab vedotin
T419	duration 39449 39455	4-week
T420	dose 39513 39531	0.5, 5 or 10 mg/kg
T421	nanoparticle 39532 39552	brentuximab vedotin,
T422	dose 39706 39720	5 and 10 mg/kg
T423	nanoparticle 39724 39744	brentuximab vedotin.
T424	dose 39819 39829	1.8 mg/kg,
T425	indication 39941 39957	Hodgkin Lymphoma
T426	tradename 39974 39982	ADCETRIS
T427	indication 40000 40002	HL
T428	dose 40162 40171	1.8 mg/kg
T429	tradename 40175 40183	ADCETRIS
T430	routeofadministration 40184 40197	intravenously
T431	frequency 40214 40228	every 3 weeks.
T432	indication 41032 41048	Hodgkin Lymphoma
T433	indication 41338 41377	Systemic Anaplastic Large Cell Lymphoma
T434	tradename 41394 41402	ADCETRIS
T435	indication 41429 41434	sALCL
T436	indication 41545 41550	sALCL
T437	dose 41630 41639	1.8 mg/kg
T438	tradename 41643 41651	ADCETRIS
T439	routeofadministration 41665 41678	intravenously
T440	frequency 41695 41709	every 3 weeks.
T441	indication 42780 42819	Systemic Anaplastic Large Cell Lymphoma
T442	tradename 43293 43301	ADCETRIS
T443	nanoparticle 43303 43323	brentuximab vedotin)
T444	nanoparticle 43504 43524	brentuximab vedotin.
T445	tradename 43650 43658	ADCETRIS
T446	adversereaction 43785 43806	Peripheral neuropathy
T447	tradename 43829 43837	ADCETRIS
T448	adversereaction 43850 43872	peripheral neuropathy.
T449	adversereaction 44054 44071	Fever/Neutropenia
T450	adversereaction 44132 44137	fever
T451	adversereaction 44343 44361	Infusion reactions
T452	adversereaction 44458 44476	infusion reactions
T453	adversereaction 44606 44620	Hepatotoxicity
T454	adversereaction 44675 44688	liver injury,
T455	adversereaction 44824 44866	Progressive multifocal leukoencephalopathy
T456	tradename 44896 44904	ADCETRIS
T457	adversereaction 45352 45364	Pancreatitis
T458	tradename 45522 45530	ADCETRIS
T459	tradename 45577 45585	ADCETRIS
T460	tradename 45743 45751	ADCETRIS
T461	company 45816 45838	Seattle Genetics, Inc.
T462	tradename 45891 45900	ADCETRIS,
T463	company 45901 45917	Seattle Genetics
T464	company 45955 45977	Seattle Genetics, Inc.
